The Solubility of Several Barbituric Acid Derivatives in Hydroalcoholic Mixtures

Total Page:16

File Type:pdf, Size:1020Kb

The Solubility of Several Barbituric Acid Derivatives in Hydroalcoholic Mixtures University of Rhode Island DigitalCommons@URI Open Access Master's Theses 1969 The Solubility of Several Barbituric Acid Derivatives in Hydroalcoholic Mixtures Thomas L. Breon University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/theses Recommended Citation Breon, Thomas L., "The Solubility of Several Barbituric Acid Derivatives in Hydroalcoholic Mixtures" (1969). Open Access Master's Theses. Paper 183. https://digitalcommons.uri.edu/theses/183 This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. ( THE SOLUBILITY OF SEVER...l'l,L BARBI'TURIC ACID DERIVATIVES I N HYDROA LCOI10LIC MIX'l'URES BY THOMAS L. BREON ( A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE IN PHARMACEUTICAL SCIENCES UNIVERSI'l'Y OF RHODE ISL..A.b<'D ( 1969 TITLE ABSTRACT ( SOLUBILITY OF SEVERAL BARBITURATES ( ( ·MASTER OF SCIENCE THESIS OF THOMAS L. BREON Approved: Thesis Committee: Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1969 ( ABSTRACT The solubility profiles for metharbital, butabar- bital, thiopental and thiamylal were determined in ethanol- 0 . w·ater solvent. systems at 25 c, in an attempt to define an approximate correlation between therapeutic activity and various solubility relationships. The relative lipophilic- ity of a drug molecule is an important factor in the physical and chemical processes involved when the therapeutic agent is introduced into a biological system. Binary solvent ( mixtures aid in delineating the relative polarity, in terms of dielectric constants, of these drugs. Spectrophotometric and, where applicable, gravimetric analyses, were utilized to determine the concentration of drug, in mg./ml., in the 41 solvent systems ranging in composition from pure ethanol to pure water. The dielectric requirement (DR) of the bar- biturates investigated, and thos e reported for barbital and vinbarbital, illustrated an approximate inverse relationship with the number of carbon atoms in the molecule. A similar correlation was found with the solubilities in pure water, and the ratios of the solubilities in ethanol and at the DR ( ii ( to the solubility in water. The therapeutic indices of duration of action and the period of time involved between administration of the drug and the time when the activity is first manifested, increased as the relative polarity of these barbiturates declined. The duration of these pharrna- cological parameters were also found to increase with a corresponding reduction in the hydrophilic nature of this series of compounds. ( iii TABLE OF CONTENTS PAGE ABSTRACT ii 'l'ABLE OF CONTENTS . iv LIS':l'S OF 'l.1 ABLES • v LIS'l1 OF FIGURES . viii I. INTRODUCTION 1 II. PAST WORK . 3 ( III. EXPERIMENTAL 15 IV. DISCUSSION 21 V. SUMMARY .. 88 VI. REFERENCES 90 VII. APPENDIX 95 A. Computer Program Calculating Least Squares . • . 96 B. Program Calculating Concentrations from Absorbances . 97 c. Program computing Ayerages and Standard Dev iation~ . 98 D. Program Computing Differences 98 E. Description of Polynomial Regression Program . • 99 F. Program calculating Ratios 99 iv ( LIST OF TABLES TABLE PAGE I. Ultraviolet absorption maxima in milli­ microns, determined spectrophotometrically compa red with literature values . 19 II. Substituents found in the noted positions for Barbituric Acid derivatives used in this study 22 III. Solubility of Barbital in ethanol-water mixtures in mg./ml. at 25°c, as a function of w/w percent water and dielectric con­ stant . 25 ( IV. Solubility of Metharbital in ethanol-water mixtures in mg./ml. at 25°c, as a function of w/w percent water and dielectric con­ stant . 28 v. Solubility of Butabarbital in ethanol-water 0 mixtures in mg./ml. at 2s c, as a function of w/w percent water and dielectric con­ stant . 34 VI. Solubility of Vinbarbital. in ethanol-water mixtures. in. mg. I m1 . at 2 5 ° c, as a function· of w/w percent wate r and dielectric con­ stant . 36 VII. Solubility of Thiopental in ethanol-water 0 mixtures in mg./ml. at 2s c, as a function of w/w percent water . and dielectric con­ stant . 40 v ( TABLE PAGE VIII. Solubility of Thiamvlal in ethanol-water mixtures in mg./ml.~ at 25°c, as a function of w/w percent water and dielectric con- stant ·. 43 IX. Solubilitv of Barbituric Acid in ethanol- wa t~r mix~ures in mg./ml. at 25°c, as a function.of w/w percent water and dielectric constant 46 X. Rates of change in solubility in mg./percent w/w water, calculated from the linear range of the solubility profiles . 49 XI. Differences in the solubility of Metharbi tal 0 and Barbital in mg./ml. at 2s c, as a function of percent w/w water and dielectric constant. 51 XII. Difference in the solubility of Butabarbital and Barbital in rng./ml. at 25°c, as a ( function of percent w/w water and dielectric con st ant . 54 XIII. Solubility of Vinbarbital in ethanol-water mixtures in rng./rnl. at 25°c, computed from a polynomial , versus w/w percent water and dielectric constant . 58 XIV. Differences in the solubility of Vinbarbital and Barbital in mg./rnl. at 25°c, as a function of percent w/w water and dielectric constant . • . 59 xv. Differences in the solubility of Thiopental and Barbital in mg./ml. at 25°c, as a function of percent w/w water and dielectric con- stant . .· • . 62 XVI. Differences in the solubility of Thiamylal and Barbital in mg./ml. at 25°c, as a function of percent w/w water and die- lectric constant . 65 ( vi ( TABLE PAGE XVII. Ratios of the solubilit y of Me tharbital to 0 Ba rbital at 2s c, as a fun ction of per­ cent w/w water a nd die lectric constant 69 XVIII. Ratios of the s olubility of Butabarbital to Barbital at 25°c, as a f unction of p ercent w/w wate r and dielectric c on­ sta nt . 71 XIX. Ra tios of the solubilit y of Vinbarbital 0 to Barbital at 2s c, as a function of percent w/w water and dielectric constant . 74 XX. Ra t ios of the solubility of Thiopental to Ba r b ital at 25° c, as a function of percent w/w water and dielectric con­ stant . 77 X...XI. Ratios o f the solubility of Thiamylal to 0 Barbital at 2s c, as a function of per­ ( cent w/w water and dielectric constant 79 XXII. Dielectric requirement, the solubilities in absolute ethanol, water and at the dielectric requirement in mg . /ml., as a function of the duration and onset of action 82 XXIII. Therapeutic action, and the ratios of the solubility in ethanol and at the dielectric requirement to the solubility in water 85 vii ( LIST OF FIGURES FIGURES PAGE Solubility of Barbital at 25°c in mg./ml. as a function of composition (w/w) for ethanol-water mixtures . · . 26 2. Solubility of Metharbital at 25°c in mg. /ml. as a function of composition (w/w) for ethanol-water mixtures . 29 3. Enol-keto tautomerism of the Barbituric Acid derivatives . 31 4. Solubility of Butabarbital at 25°c in mg. /ml. in the binary solvent systems ·c studied . 35 5. Solubility of Vinbarbital at 25°c in mg./ml. versus percent water by weight in the binary solvents studied . 37 0 6. Solubility of Thiopental at 25 c in mg./ml. as a function of composition (w/w) for ethanol-water mixtures . 41 7. Solubility of Thiamylal at 25°c in mg. /ml. as a function of percent w/w water 44 8. Solubility of Barbituric Acid at 25°c in mg./ml. as a function of composition (w/w) for ethanol-water mixtures . 47 9. Plot of the difference of the magnitude of s 1- ubility for Metharbital and Barbital in rn j. /ml. for the binary systems studied 52 ( viii f FIGURE PAGE 10. Plot of the difference in the magnitude of solubility for Butabarbital and Bar­ bital in mg./ml. as a function of com­ position (w/w) for ethanol-water mixtures 55 11. Difference in the magnitude of solubility for Vinbarbital and Barbital expressed in mg. /ml. plotted as a function of percent water by weight . 60 12. Plot of the difference in the magnitude of solubility for Thiopental and Barbital in mg./ml. for the binary systems investigated 63 13. Plot of the difference of the magnitude of solubility for Thiarny l al and Barbital ex­ presse d in rng./ml. as a f unction of solvent composition . • . 66 14. Solubili ty of Metharbita l relative tq the solubility o f Barbital versus percent by ( weight water in the solvent systems studied. • . 70 15. Ratio of the solubility of Butabarbital to the solubility of Barbital as a function of composition (w/w) for ethanol-water systems. 72 16. Plot of the solubility of Vinbarbital rela­ tive to the solubility of Barbital for each of the binary systems studied . 75 17. Solubility of Thiopental relative to the solubility of Barbital plotted as a function of solvent composition 78 18. Solubility of Thiamylal relative to the solubility of Barbital versus percent water by weight . so I \ ix t I. INTRODUCTION The pharmacological action exerted by a drug molecule in contact with a biological system is the net result of the interaction s and extent of interactions with the c omplex biological environment. The degree as well as the rate of intera ction is governed by many parameters, many of which de­ pend on the physical and chemical properties associated with the drug molecule.
Recommended publications
  • Journal of Pharmacology and Experimental Therapeutics
    Journal of Pharmacology and Experimental Therapeutics Molecular Determinants of Ligand Selectivity for the Human Multidrug And Toxin Extrusion Proteins, MATE1 and MATE-2K Bethzaida Astorga, Sean Ekins, Mark Morales and Stephen H Wright Department of Physiology, University of Arizona, Tucson, AZ 85724, USA (B.A., M.M., and S.H.W.) Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina NC 27526, USA (S.E.) Supplemental Table 1. Compounds selected by the common features pharmacophore after searching a database of 2690 FDA approved compounds (www.collaborativedrug.com). FitValue Common Name Indication 3.93897 PYRIMETHAMINE Antimalarial 3.3167 naloxone Antidote Naloxone Hydrochloride 3.27622 DEXMEDETOMIDINE Anxiolytic 3.2407 Chlordantoin Antifungal 3.1776 NALORPHINE Antidote Nalorphine Hydrochloride 3.15108 Perfosfamide Antineoplastic 3.11759 Cinchonidine Sulfate Antimalarial Cinchonidine 3.10352 Cinchonine Sulfate Antimalarial Cinchonine 3.07469 METHOHEXITAL Anesthetic 3.06799 PROGUANIL Antimalarial PROGUANIL HYDROCHLORIDE 100MG 3.05018 TOPIRAMATE Anticonvulsant 3.04366 MIDODRINE Antihypotensive Midodrine Hydrochloride 2.98558 Chlorbetamide Antiamebic 2.98463 TRIMETHOPRIM Antibiotic Antibacterial 2.98457 ZILEUTON Antiinflammatory 2.94205 AMINOMETRADINE Diuretic 2.89284 SCOPOLAMINE Antispasmodic ScopolamineHydrobromide 2.88791 ARTICAINE Anesthetic 2.84534 RITODRINE Tocolytic 2.82357 MITOBRONITOL Antineoplastic Mitolactol 2.81033 LORAZEPAM Anxiolytic 2.74943 ETHOHEXADIOL Insecticide 2.64902 METHOXAMINE Antihypotensive Methoxamine
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • 2019 Complete Law Book
    Message from the Board Chairman Welcome to the Gem State! Thank you for downloading the Idaho Pharmacy Law Book, which compiles select state laws relevant to the practice of pharmacy in or into Idaho. The Board acknowledges that changes in the education and training of pharmacists, as well as rapid advancements in the technology environment, have required a change in approach to regulating the practice of pharmacy. The Board continues to embrace those changes and the growth of our profession. Rule 27.01.01.100 provides guidance to licensees and registrants as they determine whether a specific act is permissible. First, a licensee or registrant should consider whether the act is expressly prohibited by any state or federal law. If an act is not expressly prohibited, the licensee should consider whether: • The act is consistent with the licensee or registrant’s education, training or practice experience; and • Performance of the act is within the accepted standard of care that would be provided in a similar setting by a reasonable and prudent licensee or registrant with similar education, training and experience. Two questions that may help licensee or registrant’s successfully navigate this change in approach from prescriptive rules to professional judgment follow: 1. If someone asks why I made this decision, can I justify it as being consistent with good patient care and with law? 2. Would this decision withstand a test of reasonableness (e.g., would another prudent pharmacist make the same decision in this situation)? You should consult an attorney if you have questions as to the legality of your actions under the laws and rules regulating pharmacy in the State of Idaho.
    [Show full text]
  • And Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav™)
    Louisiana Medicaid Sodium Oxybate (Xyrem®) and Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav™) The Louisiana Uniform Prescription Drug Prior Authorization Form should be utilized to request clinical authorization for sodium oxybate (Xyrem®) and calcium, magnesium, potassium and sodium oxybates (Xywav™). These agents have Black Box Warnings and are subject to Risk Evaluation and Mitigation Strategy (REMS) under FDA safety regulations. Please refer to individual prescribing information for details. Approval Criteria • The recipient is 7 years of age or older on date of request; AND • The recipient has a documented diagnosis of narcolepsy or cataplexy; AND • The prescribing provider is a Board-Certified Neurologist or a Board-Certified Sleep Medicine Physician; AND • By submitting the authorization request, the prescriber attests to the following: o The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; AND o All laboratory testing and clinical monitoring recommended in the product prescribing information have been completed as of the date of the request and will be repeated as recommended; AND o The recipient has no inappropriate concomitant drug therapies or disease states. Duration of initial authorization approval: 3 months Reauthorization Criteria • The recipient continues to meet all initial approval criteria; AND
    [Show full text]
  • Prescription Drug Management
    Check out our new site: www.acllaboratories.com Prescription Drug Management Non Adherence, Drug Misuse, Increased Healthcare Costs Reports from the Centers for DiseasePrescription Control and Prevention (CDC) say Drug deaths from Managementmedication overdose have risen for 11 straight years. In 2008 more than 36,000 people died from drug overdoses, and most of these deaths were caused by prescription Nondrugs. Adherence,1 Drug Misuse, Increased Healthcare Costs The CDC analysis found that nearly 40,000 drug overdose deaths were reported in 2010. Prescribed medication accounted for almost 60 percent of the fatalities—far more than deaths from illegal street drugs. Abuse of painkillers like ReportsOxyContin from and the VicodinCenters forwere Disease linked Control to the and majority Prevention of the (CDC) deaths, say deaths from according to the report.1 medication overdose have risen for 11 straight years. In 2008 more than 36,000 people died from drug overdoses, and most of these deaths were caused by prescription drugs. 1 A health economics study analyzed managed care claims of more than 18 million patients, finding that patients undergoing opioid therapyThe CDCfor chronic analysis pain found who that may nearly not 40,000 be following drug overdose their prescription deaths were regimenreported in 2010. Prescribed medication accounted for almost 60 percent of the fatalities—far more than deaths have significantly higher overall healthcare costs. from illegal street drugs. Abuse of painkillers like OxyContin and Vicodin were linked to the majority of the deaths, according to the report.1 ACL offers drug management testing to provide information that can aid clinicians in therapy and monitoring to help improve patientA health outcomes.
    [Show full text]
  • Additional Requested Drugs
    PART 1 PART PATIENT PRESCRIBED MEDICATIONS: o ACTIQ o DESIPRAMINE o HYDROCODONE o MORPHINE o ROXICODONE o ADDERALL o DIAZEPAM* o HYDROMORPHONE o MS CONTIN o SOMA o ALPRAZOLAM* o DILAUDID o IMIPRAMINE o NEURONTIN o SUBOXONE o AMBIEN o DURAGESIC o KADIAN o NORCO o TEMAZEPAM o AMITRIPTYLINE o ELAVIL o KETAMINE o NORTRIPTYLINE o TRAMADOL* o ATIVAN o EMBEDA o KLONOPIN o NUCYNTA o TYLENOL #3 o AVINZA o ENDOCET o LORAZEPAM o OPANA o ULTRAM o BUPRENEX o FENTANYL* o LORTAB o OXYCODONE o VALIUM o BUPRENORPHINE o FIORICET o LORCET o OXYCONTIN o VICODIN o BUTRANS o GABAPENTIN o LYRICA o PERCOCET o XANAX o CLONAZEPAM* o GRALISE o METHADONE o RESTORIL TO RE-ORDER CALL RITE-PRINT 718/384-4288 RITE-PRINT CALL TO RE-ORDER ALLIANCE DRUG PANEL (SEE BELOW) o ALCOHOL o BARBITURATES o ILLICITS o MUSCLE RELAXANTS o OPIODS (SYN) ETHANOL PHENOBARBITAL 6-MAM (HEROIN)* CARISPRODOL FENTANYL* BUTABARBITAL a-PVP MEPROBAMATE MEPERIDINE o AMPHETAMINES SECOBARBITAL BENZOYLECGONINE NALOXONE AMPHETAMINE PENTOBARBITAL LSD o OPIODS (NATURAL) METHADONE* METHAMPHETAMINE BUTALBITAL MDA CODEINE METHYLPHENEDATE MDEA MORPHINE o NON-OPIOID o BENZODIAZEPINES MDMA ANALGESICS o OPIODS (SEMI-SYN) o ANTICONVULSIVES ALPRAZOLAM* MDPV TRAMADOL BUPRENORPHINE* GABAPENTIN CLONAZEPAM* MEPHEDRONE TAPENTADOL DIHROCODEINE PREGABALIN DIAZEPAM METHCATHINONE DESOMORPHINE o NON-BENZODIAZEPINE FLUNITRAZEPAM* METHYLONE HYDROCODONE HYPNOTIC o ANTIDEPRESSANTS FLURAZEPAM* PCP HYDROMORPHONE ZOLPIDEM* AMITRIPTYLINE LORAZEPAM THC* OXYCODONE DOXEPIN OXAZEPAM CBD ° OXYMORPHONE o MISCELLANEOUS DRUGS IMIPRIMINE
    [Show full text]
  • Nembutal [Pentobarbital] Injection and Seconal [Secobarbital] Capsules
    Pharmacy Benefit Coverage Criteria Effective Date .......................................... 12/1/2020 Next Review Date… ................................... 12/1/2021 Coverage Policy Number ................................ P0095 Nembutal [pentobarbital] injection and Seconal [secobarbital] capsules Table of Contents Related Coverage Resources Overview .............................................................. 1 Coverage Policy ................................................... 1 FDA Summary ..................................................... 1 General Background ............................................ 2 References .......................................................... 2 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific
    [Show full text]
  • Control Substance List
    Drugs DrugID SubstanceName DEANumbScheNarco OtherNames 1 1-(1-Phenylcyclohexyl)pyrrolidine 7458 I N PCPy, PHP, rolicyclidine 2 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 9663 I Y PEPAP, synthetic heroin 3 1-[1-(2-Thienyl)cyclohexyl]piperidine 7470 I N TCP, tenocyclidine 4 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 7473 I N TCPy 5 13Beta-ethyl-17beta-hydroxygon-4-en-3-one 4000 III N 6 17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane 4000 III N 7 17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane 4000 III N 8 17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene 4000 III N 9 17Alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hyd 4000 III N 10 17Alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy- 4000 III N 17-Alpha-methyl-1-testosterone 11 19-Nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene; 4000 III N 12 19-Nor-4-androstenedione (estr-4-en-3,17-dione) 4000 III N 13 19-Nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene; 4000 III N 14 19-Nor-5-androstenedione (estr-5-en-3,17-dione) 4000 III N 15 1-Androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1- 4000 III N 16 1-Androstenedione (5alpha-androst-1-en-3,17-dione) 4000 III N 17 1-Methyl-4-phenyl-4-propionoxypiperidine 9661 I Y MPPP, synthetic heroin 18 1-Phenylcyclohexylamine 7460 II N PCP precursor 19 1-Piperidinocyclohexanecarbonitrile 8603 II N PCC, PCP precursor 20 2,5-Dimethoxy-4-(n)-propylthiophenethylamine 7348 I N 2C-T-7 21 2,5-Dimethoxy-4-ethylamphetamine 7399 I N DOET 22 2,5-Dimethoxyamphetamine 7396 I N DMA, 2,5-DMA 23 3,4,5-Trimethoxyamphetamine
    [Show full text]
  • The Cardiorespiratory and Anesthetic Effects of Clinical and Supraclinical
    THE CARDIORESPIRATORY AND ANESTHETIC EFFECTS OF CLINICAL AND SUPRA CLINICAL DOSES OF ALF AXALONE IN CYCLODEXTRAN IN CATS AND DOGS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Laura L. Nelson, B.S., D.V.M. * * * * * The Ohio State University 2007 Dissertation Committee: Professor Jonathan Dyce, Adviser Professor William W. Muir III Professor Shane Bateman If I have seen further, it is by standing on the shoulders of giants. lmac Ne1vton (1642-1727) Copyright by Laura L. Nelson 2007 11 ABSTRACT The anesthetic properties of steroid hormones were first identified in 1941, leading to the development of neurosteroids as clinical anesthetics. CT-1341 was developed in the early 1970’s, featuring a combination of two neurosteroids (alfaxalone and alphadolone) solubilized in Cremophor EL®, a polyethylated castor oil derivative that allows hydrophobic compounds to be carried in aqueous solution as micelles. Though also possessing anesthetic properties, alphadolone was included principally to improve the solubility of alfaxalone. CT-1341, marketed as Althesin® and Saffan®, was characterized by smooth anesthetic induction and recovery in many species, a wide therapeutic range, and no cumulative effects with repeated administration. Its cardiorespiratory effects in humans and cats were generally mild. However, it induced severe hypersensitivity reactions in dogs, with similar reactions occasionally occurring in cats and humans. The hypersensitivity reactions associated with this formulation were linked to Cremophor EL®, leading to the discontinuation of Althesin® and some other Cremophor®-containing anesthetics. More recently, alternate vehicles for hydrophobic drugs have been developed, including cyclodextrins.
    [Show full text]
  • 2019 01 07 Classification Substances
    DRUG TESTING STANDARDS AND PRACTICES PROGRAM. Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule. January, 2019 (V.14.0) © ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2019. Association of Racing Commissioners International 2365 Harrodsburg Road- B450 Lexington, Kentucky, USA www.arci.com Page 1 of 66 Preamble to the Uniform Classification Guidelines of Foreign Substances The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991. "The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalities to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered.
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • House Bill No.11 (2019)
    LEGISLATURE OF THE STATE OF IDAHO Sixty-fifth Legislature First Regular Session - 2019 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO. 11 BY HEALTH AND WELFARE COMMITTEE 1 AN ACT 2 RELATING TO CONTROLLED SUBSTANCES; AMENDING SECTION 37-2705, IDAHO CODE, TO 3 REVISE THE LIST OF SCHEDULE I CONTROLLED SUBSTANCES; AMENDING SECTION 4 37-2709, IDAHO CODE, TO PROVIDE AN EXCLUSION AND TO MAKE A TECHNICAL 5 CORRECTION; AMENDING SECTION 37-2713, IDAHO CODE, TO REVISE THE LIST OF 6 SCHEDULE V DRUGS AND SUBSTANCES; AND DECLARING AN EMERGENCY. 7 Be It Enacted by the Legislature of the State of Idaho: 8 SECTION 1. That Section 37-2705, Idaho Code, be, and the same is hereby 9 amended to read as follows: 10 37-2705. SCHEDULE I. (a) The controlled substances listed in this sec- 11 tion are included in schedule I. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters, and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-pip- 17 eridinyl]-N-phenylacetamide); 18 (2) Acetylmethadol; 19 (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylac- 20 etamide); 21 (4) Allylprodine; 22 (5) Alphacetylmethadol (except levo-alphacetylmethadol also known as 23 levo-alpha-acetylmethadol, levomethadyl acetate or LAAM); 24 (6) Alphameprodine; 25 (7) Alphamethadol; 26 (8) Alpha-methylfentanyl; 27 (9) Alpha-methylthiofentanyl
    [Show full text]